Relación entre el polimorfismo DRD2/ANKK1 y el desarrollo de complicaciones motoras en enfermedad de Parkinson

De Lau, 2006, Epidemiology of Parkinson's disease, Lancet Neurol, 5, 525, 10.1016/S1474-4422(06)70471-9 Hely, 2005, Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years, Mov Disord, 20, 190, 10.1002/mds.20324 Kaiser, 2003, L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism, Neurology, 60, 1750, 10.1212/01.WNL.0000068009.32067.A1 Ahlskog, 2001, Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature, Mov Disord, 16, 448, 10.1002/mds.1090 Cervantes-Arriaga, 2012, Fluctuaciones motoras en enfermedad de Parkinson, Rev Med Inst Mex Seguro Soc, 50, 141 Cervantes-Arriaga, 2012, Incidencia y determinantes de discinesias inducidas por levodopa en una cohorte retrospectiva de pacientes mexicanos con enfermedad de Parkinson, Rev Invest Clin, 64, 220 Jankovic, 2005, Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations, Mov Disord, 20, S11, 10.1002/mds.20458 Oliveri, 1999, Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD, Neurology, 53, 1425, 10.1212/WNL.53.7.1425 Fujii, 1999, Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease, Clin Genet, 56, 394, 10.1034/j.1399-0004.1999.560508.x Makoff, 2000, Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease, Pharmacogenetics, 10, 43, 10.1097/00008571-200002000-00006 Wang, 2001, Association study of dopamine D2 D3 receptor gene polymorphisms with motor fluctuations in PD, Neurology, 56, 1757, 10.1212/WNL.56.12.1757 Neville, 2004, Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1, Hum Mutat, 23, 540, 10.1002/humu.20039 Thompson, 1997, D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele, Pharmacogenetics, 7, 479, 10.1097/00008571-199712000-00006 Ritchie, 2003, Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics, Neurochem Res, 28, 73, 10.1023/A:1021648128758 Pohjalainen, 1998, The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers, Mol Psychiatry, 3, 256, 10.1038/sj.mp.4000350 Ishiguro, 1998, Association study between the –141C Ins/Del and TaqI A polymorphisms of the dopamine D2 receptor gene and alcoholism, Alcohol Clin Exp Res, 22, 845 Gibb, 1988, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease, J Neurol Neurosurg Psychiatry, 51, 745, 10.1136/jnnp.51.6.745 Hoehn, 2001, Parkinsonism: Onset, progression, and mortality. 1967, Neurology, 57, S11 Goetz, 2008, Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results, Mov Disord, 23, 2129, 10.1002/mds.22340 Lee, 2011, Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease, Mov Disord, 26, 73, 10.1002/mds.23400 Liu, 2009, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients, Eur J Clin Pharmacol, 65, 679, 10.1007/s00228-009-0658-z Sharma, 2010, Classifying risk factors for dyskinesia in Parkinson's disease, Parkinsonism Relat Disord, 16, 490, 10.1016/j.parkreldis.2010.06.003 Thanvi, 2007, Levodopa induced dyskinesia in Parkinson's disease: Clinical features, pathogenesis, prevention and treatment, Postgrad Med J, 83, 384, 10.1136/pgmj.2006.054759 Grevle, 2000, Allelic association between the DRD2 TaqI A polymorphism and Parkinson's disease, Mov Disord, 15, 1070, 10.1002/1531-8257(200011)15:6<1070::AID-MDS1003>3.0.CO;2-A Rieck, 2012, DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients, Pharmacogenomics, 13, 1701, 10.2217/pgs.12.149 Koning, 2012, Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients, Psychopharmacology (Berl), 219, 727, 10.1007/s00213-011-2394-1 Lencz, 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients, Am J Psychiat, 163, 529, 10.1176/appi.ajp.163.3.529 Kaplan, 2014, Sequence variants in SLC6A3 DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease, J Mol Neurosci, 53, 183, 10.1007/s12031-014-0276-9 Zappia, 2005, Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: An exploratory study, Arch Neurol, 62, 601, 10.1001/archneur.62.4.601